# Shenzhen Beimei Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-beimei-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.beimeiyaoye.com
- Total disclosed funding: $16M
- Latest round: Series B (Apr 6, 2022)
- Investors on record: 4

## About

Established in 2010, and based in Shenzhen, China, Shenzhen Beimei Pharmaceutical Co., Ltd. is a pharmaceutical company that focuses on children's prescription drugs. It has set up a professional research and development and overseas product introduction team. The company has also partnered with top 5 Indian pharmaceutical companies such as Cipla, Hetero, and European pharmaceutical companies such as DEVA Holding, EMP Pharma, LTS, MedPharma, for more than 10 pediatric drugs. In December 2022, its product, DENOSIN Oral Solution obtained the production licence B certification. In June 2023, it established its production base in Jiangsu. In July 2023, Shenzhen Beimei Pharmaceutical Co., Ltd. raised strategic investment from new investors AOSAIKANG PHARM, Jiangsu Jinqiao Private Equity Fund Management, Shenzhen Nanshan Strategic Emerging Industry Investment.

The company's pharmaceutical products are used in the respiratory, neurological, anti-infective, dermatological, hematology, gastroenterology, immunological and endocrinology. Representative drugs include oseltamivir phosphate for suspension, lacosamide Oral Solution, atomoxetine hydrochloride oral solution, sultamicillin for suspension, and oseltamivir phosphate for oral suspension.

## Funding rounds

- Series B, Apr 6, 2022, $16M — Efung Capital, Lianrun Dongfang Equity Investment Fund Management, Qingfeng (Zhuhai) Capital Investment Management Co., Ltd., Hainan Jinbei Enterprise Management Partnership

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Lianrun Dongfang Equity Investment Fund Management (https://capitalatlas.ai/funds/lianrun-dongfang-equity-investment-fund-management) — Series B
- Qingfeng (Zhuhai) Capital Investment Management Co., Ltd. — Series B
- Hainan Jinbei Enterprise Management Partnership — Series B